Aortic & peripheral vascular disease
1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies
Authors' conclusion
1-year outcomes following TADV with the LimFlow System demonstrated durable AFS and limb salvage rates, and improvement in clinical symptoms in no-option CLTI patients who often face major amputation or palliative care.
Study context
- Population
- Patients with Rutherford class 5/6 chronic limb-threatening ischemia (CLTI) and independently assessed no-option statuspooled analysis n = 137
- Participants
- 105 patients
- Outcome
- Amputation-free survival (AFS), limb salvage and survival
- Follow-up
- 1 year
Methodological detailsmulticentre
- Multicentre
Pooled result
As reported in the abstract
AFS, limb salvage and survival (PROMISE II)
Amputation-free survival (AFS)
54.2%
95% CI 45.2–65.1%
Limb salvage
68.7%
95% CI 59.8–78.9%
Survival
79.0%
95% CI 70.2–88.8%
Further pooled results
AFS, limb salvage and survival (pooled PROMISE I, II and UK, n = 137) · 1 year
- AFS
- 66.1% (95% CI: 58.4-74.9%)
- Limb salvage
- 74.4% (95% CI: 67.1-82.5%)
- Survival
- 88.9% (95% CI: 82.9-95.2%)
- Patient-level pooled analysis
Clinical symptoms and wound status · 1 year
- Clinical symptoms and wound status showed improvement through 1 year
Original publication
1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies. JACC Cardiovasc Interv. Published 14 July 2025. doi:10.
Summarised from the published abstract; every number is checked against it